Your browser doesn't support javascript.
loading
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
Garcia-Carbonero, Rocio; Bazan-Peregrino, Miriam; Gil-Martín, Marta; Álvarez, Rafael; Macarulla, Teresa; Riesco-Martinez, Maria C; Verdaguer, Helena; Guillén-Ponce, Carmen; Farrera-Sal, Martí; Moreno, Rafael; Mato-Berciano, Ana; Maliandi, Maria Victoria; Torres-Manjon, Silvia; Costa, Marcel; Del Pozo, Natalia; Martínez de Villarreal, Jaime; Real, Francisco X; Vidal, Noemí; Capella, Gabriel; Alemany, Ramon; Blasi, Emma; Blasco, Carmen; Cascalló, Manel; Salazar, Ramon.
  • Garcia-Carbonero R; Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain.
  • Bazan-Peregrino M; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.
  • Gil-Martín M; Medical Oncology Department, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Álvarez R; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Macarulla T; Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
  • Riesco-Martinez MC; Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Verdaguer H; Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain.
  • Guillén-Ponce C; Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Farrera-Sal M; Hospital Ramon y Cajal, Madrid, Spain.
  • Moreno R; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.
  • Mato-Berciano A; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Maliandi MV; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Torres-Manjon S; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Costa M; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Del Pozo N; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.
  • Martínez de Villarreal J; VCN Biosciences, Sant Cugat del Vallès, Barcelona, Spain.
  • Real FX; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Vidal N; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Capella G; Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Alemany R; ProCure Program, Institut Catala d'Oncologia, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Blasi E; Epithelial Carcinogenesis Group, Molecular Oncology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain.
  • Blasco C; Epithelial Carcinogenesis Group, Molecular Oncology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain.
  • Cascalló M; Epithelial Carcinogenesis Group, Molecular Oncology Programme, Spanish National Cancer Research Centre-CNIO, Madrid, Spain.
  • Salazar R; Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
J Immunother Cancer ; 10(3)2022 03.
Article en En | MEDLINE | ID: mdl-35338084
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article